David E Elder

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5845/publications.pdf

Version: 2024-02-01

103	4,894	159585 30	98798 67
papers	citations	h-index	g-index

105	105	105	5358
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Local recurrence in patients undergoing wide excision and sentinel lymph node biopsy for cutaneous malignant melanoma: AÂsingle-center, retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, 87, 247-250.	1.2	1
2	ASO Visual Abstract: Prognostic Significance of Primary-Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. Annals of Surgical Oncology, 2022, , 1.	1.5	0
3	Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. Annals of Surgical Oncology, 2022, 29, 5207-5216.	1.5	10
4	Dermatopathologist Perceptions of Overdiagnosis of Melanocytic Skin Lesions and Association With Diagnostic Behaviors. JAMA Dermatology, 2022, 158, 675.	4.1	7
5	Histopathological Diagnosis of Cutaneous Melanocytic Lesions: Blinded and <scp>Nonâ€Blinded</scp> Second Opinions Offer Similar Improvement in Diagnostic Accuracy. Clinical and Experimental Dermatology, 2022, , .	1.3	1
6	Immunohistochemical Profiling of Conjunctival Melanocytic Intraepithelial Lesions, Including SOX10, HMB45, Ki67, and P16. American Journal of Ophthalmology, 2021, 222, 148-156.	3.3	7
7	Terminology for melanocytic skin lesions and the <scp>MPATHâ€Dx</scp> classification schema: A survey of dermatopathologists. Journal of Cutaneous Pathology, 2021, 48, 733-738.	1.3	8
8	Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families. BMC Public Health, 2021, 21, 692.	2.9	4
9	The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of CDKN2A and CDK4. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 676-681.	2.5	3
10	Histopathologic synoptic reporting of invasive melanoma: How reliable are the data?. Cancer, 2021, 127, 3125-3136.	4.1	5
11	Melanoma in the blink of an eye: Pathologistsâ€™ rapid detection, classification, and localization of skin abnormalities. Visual Cognition, 2021, 29, 386-400.	1.6	2
12	More than just acral melanoma: the controversies of defining the disease. Journal of Pathology: Clinical Research, 2021, 7, 531-541.	3.0	10
13	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. American Journal of Surgical Pathology, 2021, 45, 1597-1605.	3.7	16
14	Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied. JAMA Dermatology, 2021, 157, 1006.	4.1	0
15	Association of Second-Opinion Strategies in the Histopathologic Diagnosis of Cutaneous Melanocytic Lesions With Diagnostic Accuracy and Population-Level Costs. JAMA Dermatology, 2021, 157, 1102.	4.1	3
16	Characterization of multiple diagnostic terms in melanocytic skin lesion pathology reports. Journal of Cutaneous Pathology, 2021, , .	1.3	2
17	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. Annals of Surgical Oncology, 2020, 27, 2915-2926.	1.5	11
18	Pathologists' agreement on treatment suggestions for melanocytic skin lesions. Journal of the American Academy of Dermatology, 2020, 82, 1435-1444.	1.2	4

#	Article	IF	Citations
19	Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. Personalized Medicine, 2020, 17, 361-371.	1.5	11
20	Malpractice and Patient Safety Concerns. American Journal of Clinical Pathology, 2020, 154, 700-707.	0.7	8
21	Urethral involvement is associated with higher mortality and local recurrence in vulvar melanoma: a single institutional experience. Human Pathology, 2020, 104, 1-8.	2.0	0
22	A case of <scp>tumorâ€toâ€tumor</scp> metastasis of cutaneous malignant melanoma. Journal of Cutaneous Pathology, 2020, 47, 1196-1199.	1.3	3
23	Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67. Human Pathology, 2020, 103, 107-119.	2.0	12
24	Factors associated with use of immunohistochemical markers in the histopathological diagnosis of cutaneous melanocytic lesions. Journal of Cutaneous Pathology, 2020, 47, 896-902.	1.3	5
25	Dermatopathologistsâ€™ Experience With and Perceptions of Patient Online Access to Pathologic Test Result Reports. JAMA Dermatology, 2020, 156, 320.	4.1	9
26	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of Pathology and Laboratory Medicine, 2020, 144, 500-522.	2.5	239
27	Staging for Melanoma - Toward a New Paradigm?. Journal of the National Cancer Institute, 2020, 112, 873-874.	6.3	2
28	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
29	Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. Journal of the American Academy of Dermatology, 2020, 83, 860-869.	1.2	5
30	Acute Photodistributed Exanthematous Pustulosis Associated With Liraglutide Treatment. JAMA Dermatology, 2019, 155, 1198.	4.1	9
31	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. Journal of the American Academy of Dermatology, 2019, 81, 386-394.	1.2	17
32	Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions. JAMA Network Open, 2019, 2, e1912597.	5.9	26
33	Draining dorsal hand pustules, nodules, and ulcers in a patient with immunosuppression. JAAD Case Reports, 2019, 5, 846-848.	0.8	1
34	Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma. Human Pathology, 2019, 88, 78-86.	2.0	1
35	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology, 2019, 46, 190-194.	1.3	6
36	Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2019, 80, 208-250.	1.2	400

#	Article	IF	Citations
37	Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00Âmm): A National Cancer Database study. Journal of the American Academy of Dermatology, 2019, 80, 433-440.	1.2	15
38	Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades. Journal of Investigative Dermatology, 2018, 138, 1620-1626.	0.7	19
39	Complexities of perceived and actual performance in pathology interpretation: A comparison of cutaneous melanocytic skin and breast interpretations. Journal of Cutaneous Pathology, 2018, 45, 478-490.	1.3	2
40	Conjunctivitis, mucosal erosions, and moist cutaneous plaques. JAAD Case Reports, 2018, 4, 117-119.	0.8	0
41	Influence of variability in assessment of Breslow thickness, mitotic rate and ulceration among US pathologists interpreting invasive melanoma, for the purpose of AJCC staging. Journal of Cutaneous Pathology, 2018, 45, 588-596.	1.3	8
42	The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex. Journal of the American Academy of Dermatology, 2018, 79, 245-251.	1.2	26
43	Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation. Journal of the American Academy of Dermatology, 2018, 79, 52-59.e5.	1.2	27
44	Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing. JAMA Dermatology, 2018, 154, 24.	4.1	50
45	Melanoma Screening and Mortality. Journal of the National Cancer Institute, 2018, 110, 1135-1136.	6.3	1
46	Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual. JAMA Network Open, 2018, 1, e180083.	5.9	27
47	Malpractice Concerns, Defensive Medicine, and the Histopathology Diagnosis of Melanocytic Skin Lesions. American Journal of Clinical Pathology, 2018, 150, 338-345.	0.7	17
48	Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma. Annals of Surgical Oncology, 2018, 25, 3469-3475.	1.5	13
49	Accuracy of Digital Pathologic Analysis vs Traditional Microscopy in the Interpretation of Melanocytic Lesions. JAMA Dermatology, 2018, 154, 1159.	4.1	20
50	Pathologists' Use of Second Opinions in Interpretation of Melanocytic Cutaneous Lesions: Policies, Practices, and Perceptions. Dermatologic Surgery, 2018, 44, 177-185.	0.8	11
51	High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Modern Pathology, 2017, 30, 634-639.	5.5	12
52	The influence of tumor regression, solar elastosis, and patient age on pathologistsâ€™ interpretation of melanocytic skin lesions. Laboratory Investigation, 2017, 97, 187-193.	3.7	3
53	Germline Variation at CDKN2A and Associations with Nevus Phenotypes amongÂMembers of Melanoma Families. Journal of Investigative Dermatology, 2017, 137, 2606-2612.	0.7	18
54	Association Between Patient Age and Lymph Node Positivity in Thin Melanoma. JAMA Dermatology, 2017, 153, 866.	4.1	50

#	Article	IF	Citations
55	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	6.4	72
56	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	6.4	117
57	Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma. Journal of Surgical Oncology, 2017, 116, 848-855.	1.7	25
58	The utilization of spitzâ€related nomenclature in the histological interpretation of cutaneous melanocytic lesions by practicing pathologists: results from the Mâ€Path study. Journal of Cutaneous Pathology, 2017, 44, 5-14.	1.3	17
59	Atypical retiform hemangioendothelioma arising in a patient with Milroy disease: a case report and review of the literature. Journal of Cutaneous Pathology, 2017, 44, 98-103.	1.3	2
60	Variation among pathologists' treatment suggestions for melanocytic lesions: A survey of pathologists. Journal of the American Academy of Dermatology, 2017, 76, 121-128.	1.2	7
61	Pathologistsâ€™ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ: British Medical Journal, 2017, 357, j2813.	2.3	302
62	Achieving consensus for the histopathologic diagnosis of melanocytic lesions: use of the modified Delphi method. Journal of Cutaneous Pathology, 2016, 43, 830-837.	1.3	36
63	Melanoma progression. Pathology, 2016, 48, 147-154.	0.6	42
64	FLT3Inhibitorâ€“Associated Neutrophilic Dermatoses. JAMA Dermatology, 2016, 152, 480.	4.1	25
65	Use of Digital Whole Slide Imaging in Dermatopathology. Journal of Digital Imaging, 2016, 29, 243-253.	2.9	23
66	Evaluation of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme for diagnosis of cutaneous melanocytic neoplasms: Results from the International Melanoma Pathology Study Group. Journal of the American Academy of Dermatology, 2016, 75, 356-363.	1.2	30
67	Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. Journal of Investigative Dermatology, 2016, 136, 2168-2172.	0.7	23
68	The selfâ€reported use of immunostains and cytogenetic testing in the diagnosis of melanoma by practicing U.S. pathologists of 10 selected states. Journal of Cutaneous Pathology, 2016, 43, 492-497.	1.3	10
69	Histopathologic and mutational analysis of a case of blue nevusâ€like melanoma. Journal of Cutaneous Pathology, 2016, 43, 776-780.	1.3	17
70	How concerns and experiences with medical malpractice affect dermatopathologists' perceptions of their diagnostic practices when interpreting cutaneous melanocytic lesions. Journal of the American Academy of Dermatology, 2016, 74, 317-324.e8.	1.2	32
71	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members ofÂMelanoma Families. Journal of Investigative Dermatology, 2016, 136, 1066-1069.	0.7	13
72	Pathology of Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 229-237.	1.5	10

#	Article	IF	Citations
73	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995.	21.4	218
74	Point: What's in a name?. Journal of the American Academy of Dermatology, 2015, 73, 513-514.	1.2	1
75	Variability in mitotic figures in serial sections of thin melanomas. Journal of the American Academy of Dermatology, 2014, 71, 1204-1211.	1.2	24
76	Reply: Surgical margins for possibly malignant melanocytic lesions and the overdiagnosis ofÂmelanoma. Journal of the American Academy of Dermatology, 2014, 71, 590.	1.2	1
77	What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing. Cancer Genetics, 2014, 207, 272-275.	0.4	16
78	The MPATH-Dx reporting schema for melanocytic proliferations and melanoma. Journal of the American Academy of Dermatology, 2014, 70, 131-141.	1.2	101
79	Pathological Staging of Melanoma. Methods in Molecular Biology, 2014, 1102, 325-351.	0.9	6
80	Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children. American Journal of Surgical Pathology, 2013, 37, 1387-1394.	3.7	96
81	Thin Melanoma. Archives of Pathology and Laboratory Medicine, 2011, 135, 342-346.	2.5	20
82	Prognostic models for melanoma. Journal of Cutaneous Pathology, 2010, 37, 68-75.	1.3	4
83	Dysplastic naevi: an update. Histopathology, 2010, 56, 112-120.	2.9	70
84	Response to â€˜Dysplastic naevi, againâ€™. Histopathology, 2010, 57, 317-318.	2.9	0
85	Common sequence variants on 20q11.22 confer melanoma susceptibility. Nature Genetics, 2008, 40, 838-840.	21.4	209
86	Identification of High-Risk Patients Among Those Diagnosed With Thin Cutaneous Melanomas. Journal of Clinical Oncology, 2007, 25, 1129-1134.	1.6	188
87	Pathology of Melanoma: Fig. 1.. Clinical Cancer Research, 2006, 12, 2308s-2311s.	7.0	24
88	Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatologic Therapy, 2005, 18, 369-385.	1.7	40
89	Biologic and Prognostic Significance of Dermal Ki67 Expression, Mitoses, and Tumorigenicity in Thin Invasive Cutaneous Melanoma. Journal of Clinical Oncology, 2005, 23, 8048-8056.	1.6	145
90	Thin Primary Cutaneous Malignant Melanoma: A Prognostic Tree for 10-Year Metastasis Is More Accurate Than American Joint Committee on Cancer Staging. Journal of Clinical Oncology, 2004, 22, 3668-3676.	1.6	187

#	Article	IF	Citations
91	The approach to the patient with a difficult melanocytic lesion. Pathology, 2004, 36, 428-434.	0.6	113
92	TIA-1 Positive Tumor-Infiltrating Lymphocytes in Nevi and Melanomas. Modern Pathology, 2000, 13, 52-55.	5.5	25
93	Tumor Progression, Early Diagnosis and Prognosis of Melanoma. Acta OncolÃ³gica, 1999, 38, 535-548.	1.8	85
94	Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer, 1995, 76, 2242-2247.	4.1	88
95	A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. Journal of the American Academy of Dermatology, 1994, 30, 707-714.	1.2	108
96	Spontaneous and induced differentiation of human melanoma cells. International Journal of Cancer, 1993, 54, 159-165.	5.1	15
97	Natural history of dysplastic nevi. Journal of the American Academy of Dermatology, 1993, 29, 51-57.	1.2	105
98	Lessons from Tumor Progression: The Invasive Radial Growth Phase of Melanoma Is Common, Incapable of Metastasis, and Indolent. Journal of Investigative Dermatology, 1993, 100, S342-S345.	0.7	130
99	Antigens Associated with Tumor Progression in Melanocytic Neoplasia. Pigment Cell & Melanoma Research, 1990, 3, 136-143.	3.6	1
100	Dysplastic naevi in a population-based survey. Cancer, 1989, 63, 1240-1244.	4.1	52
101	Dysplastic Nevus Syndromes. Pigment Cell & Melanoma Research, 1988, 1, 138-143.	3.6	0
102	GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Letters, 1986, 208, 17-22.	2.8	70
103	Dysplastic nevus syndrome: A phenotypic association of sporadic cutaneous melanoma. Cancer, 1980, 46, 1787-1794.	4.1	444